Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Authors
Keywords
Chk1, Breast cancer, Ovarian cancer, V158411, DNA repair, Triple-negative
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-08-08
DOI
10.1186/1471-2407-14-570
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
- (2014) Rebecca Rawlinson et al. BMC CANCER
- Chk1 as a new therapeutic target in triple-negative breast cancer
- (2014) Laurence Albiges et al. BREAST
- Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
- (2014) Christopher Bryant et al. Molecular Cancer
- PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
- (2013) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
- (2013) Constance King et al. INVESTIGATIONAL NEW DRUGS
- Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
- (2013) Enilze Ribeiro et al. PLoS One
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
- (2012) K Brooks et al. ONCOGENE
- Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition
- (2011) Hidetaka Shibata et al. CANCER SCIENCE
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
- (2011) T. J. Guzi et al. MOLECULAR CANCER THERAPEUTICS
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
- (2011) Matilde Murga et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
- (2011) P T Ferrao et al. ONCOGENE
- Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo
- (2011) Kurtis D. Davies et al. ONCOLOGY RESEARCH
- Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 Inactivation
- (2011) Josep V. Forment et al. PLoS One
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
- (2011) K. A. Cole et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
- (2011) Elizabeth Alli et al. BMC Pharmacology & Toxicology
- Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo
- (2010) Zizhen Feng et al. CANCER LETTERS
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- (2010) O. Gilad et al. CANCER RESEARCH
- Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
- (2010) Ana Bosch et al. CANCER TREATMENT REVIEWS
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Chk1 promotes replication fork progression by controlling replication initiation
- (2010) E. Petermann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress
- (2009) V. Leung-Pineda et al. CANCER RESEARCH
- CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
- (2009) Clark C Chen et al. Molecular Cancer
- The F Box Protein Fbx6 Regulates Chk1 Stability and Cellular Sensitivity to Replication Stress
- (2009) You-Wei Zhang et al. MOLECULAR CELL
- Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase
- (2009) Zhenjian Cai et al. MOLECULAR CELL
- G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
- (2008) N Bucher et al. BRITISH JOURNAL OF CANCER
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
- (2008) A. Blasina et al. MOLECULAR CANCER THERAPEUTICS
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now